Close

Pluristem Therapeutics (PSTI) Says Published Study Shows PLX Cells Significantly Inhibit Cancer Cell Growth

January 12, 2018 7:05 AM EST Send to a Friend
Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today announced the publication of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login